OCS
Oculis Holding AGNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
6.07
P/S
2414.73
EV/EBITDA
-11.94
DCF Value
$1.88
FCF Yield
-5.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-2858.1%
Operating Margin
-16254.4%
Net Margin
-19598.9%
ROE
-62.5%
ROA
-44.3%
ROIC
-40.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-23.3M | $-0.42 |
| FY 2025 | $0.00 | $-94.5M | $-1.81 |
| Q3 2025 | $243.0K | $-16.9M | $-0.32 |
| Q2 2025 | $261.0K | $-25.4M | $-0.49 |
Analyst Ratings
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
CH
Exchange
NASDAQ
Beta
0.21
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.